Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke

NCT06440707 · View on ClinicalTrials.gov ↗

Study Summary

Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the brain and rescue the brain tissue at risk of injury. The primary aim is to find an optimal dose of this therapy that is both adequately safe and effective on imaging markers of brain tissue rescue.

Conditions Studied

Interventions

  • DEVICE High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)
  • DEVICE Sham tDCS

Study Locations (3)

California

  • University of California- Los Angeles (UCLA) — Los Angeles

Maryland

  • Johns Hopkins Medical Center — Baltimore

North Carolina

  • Duke Medical Center Hospital — Durham

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-07-15
Est. Completion 2030-08-01
Phase Phase 2

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06440707

The ClinicalTrials.gov registry entry for NCT06440707 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 829 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions — of which High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06440707 reports 3 study locations spanning 3 distinct geographic areas — top geographies include California, Maryland, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06440707 about?

NCT06440707 is a clinical study titled "Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke". Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the de...

What is the current status of trial NCT06440707?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-07-15. Estimated completion is 2030-08-01.

What conditions does trial NCT06440707 study?

This clinical trial studies the following conditions: Acute Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06440707?

The interventions under investigation include: High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS) (DEVICE), Sham tDCS (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06440707?

This trial is sponsored by University of California, Los Angeles, which has 829 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06440707 being conducted?

This trial has 3 study locations across California, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial